Background. Candida is the most common cause of invasive fungal infection in healthcare settings and is associated with significant increases in healthcare resource utilization and attributable mortality.
Background. Up to 20% of SA isolates in the United States are penicillin-susceptible (PSSA); however, treatment with penicillin has been discouraged because of concern that routine testing may miss strains that have the capacity to produce clinically significant ß-lactamase in vivo. We performed a retrospective analysis to determine whether PCN therapy for the treatment of PSSA bacteremia was of comparable efficacy and safety to standard therapies.
Methods. We identified all episodes of SA bacteremia (March 18, 2010 -July 23, 2018 . SA penicillin susceptibility testing in our lab was performed by broth microdilution followed by nitrocefin ß-lactamase testing per CLSI guidelines on these isolates. A retrospective chart review was performed and our primary outcome was a composite endpoint of clinical success (no change in PSSA therapy due to persistent or worsening signs and symptoms, no PSSA bacteremia recurrence or persistence, and no infection-related mortality). Microbiologic failure was defined as either failure to clear bacteremia/infection or recurrence after completion of therapy. Patients were followed until last contact with our medical system, the only tertiary center in the region. We compared our rates of success, mortality, and adverse drug reaction to historical SA bacteremia controls from the literature.
Results.
PSSA accounted for 13% (130/971) of SA bloodstream episodes. Nineteen patients with PSSA (15%) were treated with PCN and 79% (15/19) achieved the primary endpoint of clinical success. Of the 4 patients who did not achieve the endpoint, 2 developed rash and were switched to a different antibiotic and 2 died from complications of sepsis. One of the patients died after clearing blood cultures but had DIC and a catastrophic intracranial hemorrhage, the other died of overwhelming sepsis after 4 days (2 days nafcillin, 2 days PCN) with continued bacteremia. Thus, our only microbiologic failure was due to early death from sepsis. Rates of success, mortality and drug reaction were similar to prior reports of alternative standard therapies (Table 1) .
Conclusion. PCN is a viable treatment option for PSSA bacteremia as identified by routine laboratory testing. Further study will include characterizing the presence of ß-lactamase in these patient's isolates.
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Clinical Characterization of Staphylococcus aureus Bacteremia in Children at an Inner-City Community Hospital
Jomi K. Oommen, PharmD; Eris Cani, BS, PharmD, BCPS; Tae E. Park, PharmD; Savita Manwani, MD and Murli Purswani, MD; BronxCare Health System, New Hyde Park, New York Session: 37. Bacteremia, CLABSI, and Endovascular Infections Thursday, October 3, 2019: 12:15 PM Background. Staphylococcus aureus bacteremia (SAB) is associated with high morbidity and mortality rates. Data on epidemiology and outcomes of SAB in children is not as well described as in adults. The primary objective of this study was to describe clinical and microbiological cure rates of SAB in hospitalized children. Secondary objectives included time to clinical and microbiological cure, mortality, proportions of methicillin-sensitive and resistant SA (MSSA, MRSA) bacteremia, and antibiotic usage pattern.
Methods. This was an electronic chart abstraction conducted at a community hospital in the South Bronx, NY, of all pediatric cases of SAB (<21 years of age) from January 1, 2010 to March 30, 2017. Demographic, clinical and microbiological data along with risk factors for bacteremia were collected. Clinical cure was defined as resolution of acute symptoms and signs of SAB and microbiological cure was defined as documentation of first negative blood culture after initiation of treatment. Standard definitions were used for hospital-acquired (HA) and community-acquired (CA) isolates of SA.
Results. Of 41 patients, neonates comprised 12%, 1-to 23-month-old infants 56% and 2-to 17-year-olds 31%. Overall, 76% of patients had bacteremia due to MSSA, and 24% MRSA. MRSA was isolated in 37% of HA SAB compared with 14% of CA SAB (P = 0.15). The two highest risk factors identified for SAB were peripherally inserted central catheters lines (PICC, 29%) and skin and soft-tissue infections (22%). SAB in the neonatal period was associated with PICC lines when compared with children outside the neonatal period (80% vs. 22%, P = 0.02). Using available data, clinical and microbiological cure rates were similar at 73%. The median time to clinical cure was 5 days (interquartile range [IQR] 2-10) and to microbiological cure, 2 days (IQR 1-4). A 2-month-old infant died (mortality 2.4%). Initial antibiotic selection was vancomycin (39%), clindamycin (39%), and nafcillin (7%). The proportion of SA resistant to clindamycin was 22%.
Conclusion. Pediatric SAB was uncommon in this community hospital experience over 7 years and is associated with PICC lines in neonates. MSSA was more prevalent than MRSA. Initial antibiotic selection had anti-staphylococcal coverage in 85% of cases, while clindamycin resistance occurred in 22% of SA isolates.
Disclosures. All authors: No reported disclosures. S114 • OFID 2019:6 (Suppl 2) • Poster Abstracts A previous single-center study had created a prediction tool to assist clinicians in identifying patients at risk for ESBL bloodstream infections. The purpose of our research project was to assess validity of this tool while also identifying risk factors for ESBL bacteremia within our own institution, which would allow for assessment of alternative prediction tools. Methods. We performed a retrospective chart review of adult patients admitted to an urban university hospital who were found to have bacteremia with Escherichia coli, Klebsiella pneumoniae, and/or Klebsiella oxytoca between October 2016 and April 2018. Demographics and comorbidities were assessed, along with other potential risk factors including exposure to antibiotics and hospitalizations within the past 6 months.
Results. A total of 214 instances of bacteremia were identified and 14% were due to ESBL organisms. Risk factors for ESBL bacteremia in our cohort included history of positive culture for ESBL (RR = 5.9) or MRSA (RR = 3.5) and antibiotic usage in the past 6 months (RR = 2.3). Patients with ESBL bacteremia were hospitalized longer (mean 16 days vs. 6 days for non-ESBL), received longer durations of antibiotic therapy (11.7 days vs. 5.3 days), and were exposed to greater numbers of different antibiotics (1.9 vs. 0.7) in the previous 6 months. Multivariate logistic regression showed that history of prior ESBL infection (OR 14.7, CI 1.8-120) and increasing number of different antibiotic classes administered in the prior 6 months (OR 4.3, CI 1.7-11.2) were significant risk factors for ESBL bacteremia. The previously created prediction tool did not sufficiently differentiate higher and lower risk for ESBL bacteremia in our cohort.
Conclusion. Although risk factors were similar, the previously derived stepwise prediction tool did not predict ESBL bacteremia in our external cohort. Point-based prediction modeling might better assess risk across institutions. Additionally, the number of different antibiotics received was associated with risk for ESBL bacteremia and should be investigated further.
Disclosures. All authors: No reported disclosures. Background. Although antibiotic-resistant (AR) Gram-negative infections are more prevalent in hemodialysis (HD) patients, there are limited data on the impact of antibiotic resistance on clinical outcomes. The primary objective of this study was evaluating 30-day readmission and 30-day all-cause mortality of HD patients with AR-Gram-negative bacteremia (GNB). The secondary objective was assessing the association of risk factors for AR-GNB and Infectious Diseases (ID) consult with the primary outcomes.
The 30-Day Readmission and 30-Day Mortality of Hemodialysis Patients with Antibiotic-Resistant Gram-Negative Bacteremia
Methods. This was a single-center, retrospective, cohort study, which enrolled adult HD patients with AR-GNB between January 1, 2010 and December 31, 2018. The AR included extended-spectrum β-lactamase (ESBL), carbapenem resistance (CR; resistant to at least one carbapenem), and multidrug resistance (MDR; resistant to at least one agent in three antibiotic classes). The risk factors for AR-GNB included: antibiotic use and long-term care facility stay within 90 days, hospitalization >30 days, central line, urinary catheter, and invasive medical device use, and severe underlying illness. Statistical analysis involved chi-square and Fisher's exact tests.
Results. A total of 90 patients were included. The most common pathogen and source were Klebsiella pneumoniae (42.2%) and urine (29.5%), respectively. The most common AR was ESBL (39.6%), followed by CR and MDR (both 29.7%). Overall, 30-day readmission and 30-day all-cause mortality were 22% and 38.5%, respectively. Long-term care facility stay within 90 days was more likely associated with 30-day readmission (odds ratio [OR] 3.46, 95% confidence interval [CI], 0.99-12.15; P = 0.048), although it was not observed with multivariate analysis (P = 0.223). Hospitalization >30 days (OR 0.25, 95% CI, 0.1-0.64; P = 0.003) and ID consult (OR 0.13, 95% CI, 0.05-0.36; P < 0.0001) were less likely associated with 30-day all-cause mortality according to multivariate analysis. Overall, MDR was more likely associated with 30-day all-cause mortality than ESBL (P = 0.02) and CR (P = 0.002).
Conclusion. To our knowledge, this is the first study evaluating the impact of AR-GNB in HD patients on 30-day readmission and 30-day all-cause mortality. Hospitalization of >30 days and having ID consult were less likely associated with 30-day all-cause mortality.
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Background. Universal follow-up blood culture (FUBC) in gram-negative bacteremia (GNB) is not recommended, but it has been routinely conducted in many acute-care hospitals. In contrast with Staphylococcus aureus bacteremia, risk factors for positive FUBC in GNB have not been well investigated. Therefore, we tried to identify the risk factors for and develop predictive scores of positive FUBC.
Methods. All adults (≥18 years-old) with GNB were identified in a tertiary-care hospital during the 2-year period, retrospectively. Death within 2 days of GNB and polymicrobial infection with gram-positive bacteria or fungus were excluded. GNB were classified into eradicable and non-eradicable source of infection groups, according to the possibility of source removal. We performed multivariate analyses for identifying risk factors for positive FUBC and built prediction scores using the coefficients of the multivariate logistic regression models.
Results. Of total 1,473 GNB, FUBC was drawn in 1,268 (86%) patients and 122 (9.6%) had positive results. In patients with eradicable source of infection, ESBLproducing microorganism, catheter-related bloodstream infection, unfavorable treatment response, and quick sequential organ failure assessment (qSOFA) score (≥2) were associated. On the other hand, administration of effective antibiotics and adequate source control were negatively associated with positive FUBC. In non-eradicable source of infection, end-stage renal disease on hemodialysis, and unfavorable treatment response were related to positive FUBC and administration of effective antibiotics was negatively associated (Table 1) . When we built prediction scores according to the coefficients, the areas under the curves were 0.864 (95% confidence interval [CI95] 0.816-0.912) and 0.792 (CI95, 0.721-0.861), respectively. When we applied a cutoff of 0, specificities/negative predictive values in eradicable and non-eradicable source of infection groups were 84.7%/95.6% and 95.5%/95.0%, respectively (Table 2) .
Conclusion. Our prediction scores based on adequate source control and use of effective antibiotics showed high specificities and negative predictive values. Therefore, we could expect these score systems to contribute to reducing unnecessary FUBC in GNB.
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A Case Series of Elizabethkingia meningosepticum Bacteremia in the Cancer Population
Dae Hyun Lee, MD 1 ; Ishita Mehra, MBBS 1 ; Sanjay Chandrasekhar, MD 1 ; Abu-Sayeef Mirza, MD 1 ; Rahul Shenoy, MBBS 1 ; Annie Topham, MD 1 ; Sowmya Nanjappa, MBBS 2 and John Greene, MD 3 ; 1 University of South Florida, Tampa, Florida; 2 University of South Florida, Moffitt Cancer Center, Tampa, Florida; 3 Moffitt Cancer Center, Tampa, Florida Session: 37. Bacteremia, CLABSI, and Endovascular Infections Thursday, October 3, 2019: 12:15 PM Background. Elizabethkingia meningosepticum (E. meningosepticum) is a ubiquitous microorganism previously known as Chryseobacterium meningosepticum. It is emerging as a pathogen responsible for bacteremia in immunocompromised patients such as cancer patients especially those with a history of prolonged hospital stay and frequent instrumentations.
Methods. A retrospective chart review of all cases over 10 years in Moffitt Cancer Center showed a total of three patients with E. meningosepticum infection.
